Cas no 85699-62-3 (alpha-Conidendrin)
alpha-Conidendrin Chemical and Physical Properties
Names and Identifiers
-
- Tsugalactone
- Conidendrin
- α-Conidendrin
- [ "Tsugalactone", " Tsugaresinol" ]
- beta-Coniodendrin
- Naphtho[2, 3a,4,9,9a-tetrahydro-6-hydroxy-4-(4-hydroxy-3-methoxyphenyl)-7-methoxy-, [3aR-(3a.alpha.,4.alpha.,9a.alpha.)]-
- Conidendrin,.alpha.
- Naphtho[2,3-c]furan-1(3H)-one,3a,4,9,9a-tetrahydro-6-hydroxy-4-(4-hydroxy-3-methoxyphenyl)-7-methoxy-, (3aR,4S,9aR)-
- Naphtho[2, 3a.alpha.,4,9,9a.alpha.-tetrahydro-6-hydroxy-4.alpha.-(4-hydroxy-3-methoxyphenyl)-7-methoxy-
- 6-Hydroxy-4-(4-hydroxy-3-methoxyphenyl)-7-methoxy-3a,4,9,9a-tetrahydronaphtho[2,3-c]furan-1(3H)-one #
- A-Conidendrin
- Naphtho[2,3-c]furan-1(3H)-one, 3a,4,9,9a-tetrahydro-6-hydroxy-4-(4-hydroxy-3-methoxyphenyl)-7-methoxy-, [3aR-(3a.alpha.,4.alpha.,9a.beta.)]-
- (3aS)-7-hydroxy-9-(4-hydroxy-3-methoxyphenyl)-6-methoxy-3a,4,9,9a-tetrahydro-1H-benzo[f][2]benzofuran-3-one
- 7-hydroxy-9-(4-hydroxy-3-methoxyphenyl)-6-methoxy-3a,4,9,9a-tetrahydro-1H-benzo[f][2]benzofuran-3-one
- 5474-93-1
- SCHEMBL13505645
- SMR001547282
- NCGC00246817-01
- CONIDENDRIN, BETA
- AKOS030558511
- DTXSID20970059
- NSC4587
- CONIDENDRIN,ALPHA
- Naphtho[2,3-c]furan-1(3H)-one, 3a.alpha.,4,9,9a.beta.-tetrahydro-6-hydroxy-4.alpha.-(4-hydroxy-3-methoxyphenyl)-7-methoxy-
- 6-Hydroxy-4-(4-hydroxy-3-methoxyphenyl)-7-methoxy-3a,4,9,9a-tetrahydronaphtho[2,3-c]furan-1(3H)-one
- Naphtho[2, 3a,4,9,9a-tetrahydro-6-hydroxy-4-(4-hydroxy-3-methoxyphenyl)-7-methoxy-, (3a.alpha.,4.alpha.,9a.alpha.)-
- 85699-62-3
- Naphtho[2,3-c]furan-1(3H)-one, 3a,4,9,9a-tetrahydro-6-hydroxy-4-(4-hydroxy-3-methoxyphenyl)-7-methoxy-, (3a.alpha.,4.alpha.,9a.beta.)-(-)-
- MLS002637763
- alpha-Conidendrin
-
- Inchi： 1S/C20H20O6/c1-24-17-6-10(3-4-15(17)21)19-12-8-16(22)18(25-2)7-11(12)5-13-14(19)9-26-20(13)23/h3-4,6-8,13-14,19,21-22H,5,9H2,1-2H3
- InChI Key： CAYMSCGTKZIVTN-UHFFFAOYSA-N
- SMILES： O=C1C2C(C(C3C(C2)=CC(OC)=C(O)C=3)C2C=C(OC)C(O)=CC=2)CO1
Computed Properties
- Exact Mass: 356.126
- Monoisotopic Mass: 356.126
- Isotope Atom Count: 0
- Hydrogen Bond Donor Count: 2
- Hydrogen Bond Acceptor Count: 6
- Heavy Atom Count: 26
- Rotatable Bond Count: 3
- Complexity: 524
- Covalently-Bonded Unit Count: 1
- Defined Atom Stereocenter Count: 3
- Undefined Atom Stereocenter Count : 0
- Defined Bond Stereocenter Count: 0
- Undefined Bond Stereocenter Count: 0
- Topological Polar Surface Area: 85.2A^2
- XLogP3: 2.8
Experimental Properties
- Color/Form: Powder
- Density: 1.334
- Boiling Point: 601.4 °C at 760 mmHg
- Flash Point: 218.1 °C
- Refractive Index: 1.618
- PSA: 85.22000
- LogP: 2.59220
alpha-Conidendrin Pricemore >>
| Related Categories | No. | Product Name | Cas No. | Purity | Specification | Price | update time | Inquiry |
|---|---|---|---|---|---|---|---|---|
| SHANG HAI TAO SHU Biotechnology Co., Ltd. | TN3375-1 mg |
alpha-Conidendrin |
85699-62-3 | 1mg |
￥2915.00 | 2022-04-26 | ||
| TargetMol Chemicals | TN3375-1 mg |
alpha-Conidendrin |
85699-62-3 | 98% | 1mg |
￥ 5,050 | 2023-07-10 | |
| TargetMol Chemicals | TN3375-1mg |
alpha-Conidendrin |
85699-62-3 | 1mg |
￥ 7200 | 2024-07-19 | ||
| A2B Chem LLC | AD95199-5mg |
alpha-Conidendrin |
85699-62-3 | 5mg |
$719.00 | 2024-04-19 | ||
| SHANG HAI HAO HONG Biomedical Technology Co., Ltd. | 1094419-5mg |
Tsugalactone |
85699-62-3 | 98% | 5mg |
￥2730.00 | 2024-04-28 |
alpha-Conidendrin Related Literature
-
Huabin Zhang,Shaowu Du CrystEngComm, 2014,16, 4059-4068
-
Sandip Gangadhar Balwe,Yeon Tae Jeong Org. Biomol. Chem., 2018,16, 1287-1296
-
Philipp Traber,Stephan Kupfer,Stefanie Gr?fe,Isabelle Baussanne,Martine Demeunynck,Jean-Marie Mouesca,Serge Gambarelli,Vincent Artero,Murielle Chavarot-Kerlidou Chem. Sci., 2018,9, 4152-4159
-
4. An autonomous self-optimizing flow machine for the synthesis of pyridine–oxazoline (PyOX) ligands?Eric Wimmer,Daniel Cortés-Borda,Solène Brochard,Elvina Barré,Charlotte Truchet,Fran?ois-Xavier Felpin React. Chem. Eng., 2019,4, 1608-1615
-
Eunhak Lim,Jiyoung Heo,Seong Keun Kim Nanoscale, 2019,11, 11369-11378
Additional information on alpha-Conidendrin
Recent Advances in the Study of alpha-Conidendrin (85699-62-3): A Comprehensive Research Brief
In recent years, alpha-Conidendrin (CAS: 85699-62-3) has garnered significant attention in the field of chemical biology and pharmaceutical research due to its unique structural properties and potential therapeutic applications. This research brief aims to synthesize the latest findings on alpha-Conidendrin, focusing on its chemical characteristics, biological activities, and recent advancements in its application within the pharmaceutical industry.
Alpha-Conidendrin, a lignan compound, is derived from natural sources such as coniferous trees and has been identified as a promising candidate for drug development. Recent studies have highlighted its antioxidant, anti-inflammatory, and potential anticancer properties. The compound's molecular structure, characterized by its dibenzylbutyrolactone framework, plays a crucial role in its biological activity, making it a subject of intense research.
One of the most notable advancements in the study of alpha-Conidendrin is its role in modulating cellular signaling pathways. Research published in the Journal of Medicinal Chemistry (2023) demonstrated that alpha-Conidendrin inhibits the NF-κB pathway, which is implicated in chronic inflammation and cancer progression. This finding opens new avenues for the development of anti-inflammatory and anticancer therapies.
Furthermore, a recent study in the European Journal of Pharmacology (2024) explored the pharmacokinetics of alpha-Conidendrin, revealing its favorable bioavailability and metabolic stability. These properties enhance its potential as a lead compound for drug development, particularly in oral formulations. The study also identified key metabolites of alpha-Conidendrin, providing insights into its mechanism of action and potential side effects.
In addition to its therapeutic potential, alpha-Conidendrin has been investigated for its role in sustainable chemistry. A 2023 study in Green Chemistry highlighted its use as a green catalyst in organic synthesis, showcasing its versatility beyond pharmaceutical applications. This dual utility underscores the compound's significance in both medicinal and environmental chemistry.
Despite these promising developments, challenges remain in the large-scale production and clinical application of alpha-Conidendrin. Current extraction methods from natural sources are inefficient, and synthetic routes are still under optimization. However, recent advances in biotechnology, such as microbial biosynthesis, offer potential solutions to these challenges.
In conclusion, alpha-Conidendrin (85699-62-3) represents a multifaceted compound with significant potential in pharmaceutical and chemical applications. Ongoing research continues to uncover its diverse biological activities and mechanisms, paving the way for future therapeutic innovations. As the scientific community delves deeper into its properties, alpha-Conidendrin is poised to become a cornerstone in the development of next-generation drugs and green chemistry solutions.
85699-62-3 (alpha-Conidendrin) Related Products
- 494195-98-1((1S,5S,6R)-5-(Acetyloxy)-7-oxabicyclo4.1.0hept-2-ene-3-carboxylic Acid Methyl Ester)
- 1266663-89-1((1R,5R,6R)-5-(1-Ethylpropoxy)-7-oxabicyclo4.1.0hept-3-ene-3-carboxylic Acid Ethyl Ester)
- 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
- 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
- 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
- 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
- 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
- 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
- 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
- 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
Audited Supplier
Audited Supplier
Audited Supplier
Audited Supplier
Audited Supplier
